Circadian Rhythm Disturbances in Patients with Alzheimer's Disease: A Review by Weldemichael, Dawit A. & Grossberg, George T.
SAGE-Hindawi Access to Research
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 716453, 9 pages
doi:10.4061/2010/716453
Review Article
Circadian Rhythm Disturbancesin Patients with Alzheimer’s
Disease:A Review
DawitA. WeldemichaelandGeorgeT. Grossberg
Department of Neurology & Psychiatry, Saint Louis University School of Medicine, St. Louis, MO 63104, USA
Correspondence should be addressed to Dawit A. Weldemichael, dweldemi@slu.edu
Received 21 April 2010; Accepted 27 July 2010
Academic Editor: Ricardo Nitrini
Copyright © 2010 D. A. Weldemichael and G. T. Grossberg.ThisisanopenaccessarticledistributedundertheCreativeCommons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Circadian Rhythm Disturbances (CRDs) aﬀect as many as a quarter of Alzheimer’s disease (AD) patients during some stage of
their illness. Alterations in the suprachiasmatic nucleus and melatonin secretion are the major factors linked with the cause
of CRDs. As a result, the normal physiology of sleep, the biological clock, and core body temperature are aﬀected. This paper
systematically discusses some of the causative factors, typical symptoms, and treatment options for CRDs in patients with AD.
This paper also emphasizes the implementation of behavioral and environmental therapies before embarking on medications to
treat CRDs. Pharmacotherapeutic options are summarized to provide symptomatic beneﬁts for the patient and relieve stress on
their families and professional care providers. As of today, there are few studies relative to CRDs in AD. Large randomized trials
are warranted to evaluate the eﬀects of treatments such as bright light therapy and engaging activities in the reduction of CRDs in
AD patients.
1.Introduction
Circadian rhythms are the regular; near 24 hs rest/wake
patterns seen in normal individuals. There is a progressive
deterioration of circadian rhythms with aging. These include
changes in the sleep wake cycle manifested by reductions
in sleep quality and impairment in cognitive performance
[1, 2]. Furthermore, exaggeration of age-related changes
is seen in Alzheimer’s Disease (AD) aﬀecting as many as
a quarter of patients during some stage of their illness.
Few sleep questionnaires-based comparison studies have
shown increased sleep disturbances in vascular cognitive
disturbances compared to AD patients. CRDs also are noted
to inﬂuence early recovery in poststroke patients [3].
Day-time agitation, night-time insomnia, and restless-
ness are among the common behavioral changes observed
in AD. Nocturnal sleep disturbance is often accompanied by
day-time napping, frequently in direct association with the
extent of dementia [4].
Circadian Rhythm Disturbances (CRDs) in AD often
present dramatically and are among the major triggers for
institutionalization [5, 6]. They are also associated with
shorter survival in long-term care residents [7, 8]a n da r e
a cause of physical and psychological burden for caregivers
[9].
2.What does CauseCRDs?
The main reason for the alteration in sleep-wake cycle is
related to alterations in the suprachiasmatic nucleus (SCN)
and melatonin secretion [10]. Though not clear, genetic risk
factors such as in AD patients who are negative for the
APOE-4 allele have also been implicated in the development
of sleep problems [11, 12].
The SCN of the anterior hypothalamus is the master clo-
ck controlling circadian rhythms in mammals. The SCN
neurons exhibit near 24-hour electrical activity. The circa-
dian inﬂuences of SCN neurons are distributed through
diﬀerenttargetorgansbyeﬀerentneuralandhumoralsignals
particularlycirculatingmelatonin.Thenucleuscontrolsmel-
atonin secretion via a multisynaptic pathway producing cha-
nges in the biological clock, core body temperature, and
sleep.
2.1. Biological Clock Changes. The activity of the SCN is
regulated by environmental signals in a 24-hour cycle and2 International Journal of Alzheimer’s Disease
runs autonomously. It resets on a daily basis via light inputs
from the retina during the day and melatonin secretion
during the night. These inputs are conveyed through the
retinohypothalamic tract (RHT) resulting in oscillation of
SCN and melatonin secretion [13–15]. The RHT originates
from the glutamatergic ganglion cells of the retina. These
cells express pituitary adenylate cyclase-activating peptide
(PACAP) which elicits phase shift signals in the SCN. There
is also a serotonergic input from the midbrain raphe nuclei
providing an arousal-dependent inﬂuence that can reset the
circadian clock and modulate the photic synchronization of
the SCN [16, 17].
The SCN contains gamma-aminobutyric acid (GABA)
and arginine vasopressin (AVP) neurons that send a direct
inhibitory projection to the nucleus of the paraventicular
nucleus of the hypothalamus [18–20]. This in turn activates
melatonin secretion by the pineal gland. Circulating mela-
tonin acts via MT1 and MT2 receptors and inhibits the ﬁring
of the SCN. Hence, it promotes sleep and resets the circadian
pacemaker. Melatonin secretion rises 2 hours before regular
bedtime and remains elevated throughout the night.
As mentioned above, alterations in the SCN and mela-
tonin secretion are assumed to be the main reason for CRD
in AD [10]. Further, there is loss of expression of AVP and
MT1 receptors in the SCN. These in turn result in a reduced
production of melatonin and disappearance of normal
melatonin rhythm [21, 22]. The functional disruption of the
SCN is even observed in the early stages of AD. The changes
in the MT1 receptor explain why large studies have failed
to show improvement in sleep-wake cycle after melatonin
administration in AD patients [23].
2.2.ChangesinSleepPhysiology. CertainsleepchangesinAD
seem to represent an exaggeration of changes that appear
with normal aging. AD patients spend an increased amount
of time in stage 1 sleep with increased number and duration
of awakenings, compared to age-matched non-AD controls
[24, 25].
With disease progression, it is also very diﬃcult to
separate EEG features of stage two sleep from stage 1 sleep.
Sleep spindles and K complexes are poorly formed. They are
also of lower amplitude, shorter duration, and much less
numerous [26, 27]. The proportion of nonrapid eye move-
ment (NREM) sleep increases with further disappearance of
the true delta wave of slow wave sleep (SWS) [24–28].
The percentage of time spent in REM sleep, which
remains stable with normal aging, is reduced in patients with
AD[26].AdecreaseinthemeanREMsleepepisodeduration
and REM sleep percentage can be due to degeneration of
the nucleus basalis of Meynert. The nucleus normally exerts
an inhibitory inﬂuence on the nucleus reticularis of the
thalamus, the rhythm generator responsible for NREM sleep
[29].
REM sleep also depends on the abundance and integrity
of the cholinergic system. The cholinergic disturbance in AD
is accompanied by worsening of REM sleep. In addition,
manysubcorticalstructuressuchasthebasalforebrain,distal
and superior raphe nucleus, and the reticular formation of
the pons and medulla seem to be involved in the initiation
of sleep and oscillation between REM and non-REM states.
All of these structures may potentially be damaged by
the degenerative changes which are part of AD. Their
deterioration may explain many of the sleep architecture and
rhythm changes in AD (see Table 1).
2.3. Core Body Temperature Changes. In accordance with
the endogenous circadian rhythm, melatonin also promotes
sleep by lowering core body temperature via peripheral vas-
cular dilatation [23]. Melatonin and core body temperature
are inversely related. Lowest body temperature occurs 1-2
hours before awakening, generally between 4 and 5 AM. This
corresponds to the maximum concentration of circulating
melatonin levels. Core body temperature and melatonin are
the two primary and measurable markers of the circadian
cycle.
The core body temperature rhythm is generally accepted
as yielding the best estimate of endogenous circadian ampli-
tude and endogenous circadian phase in human subjects
[30].
However, studies of circadian core body temperature
rhythms in human subjects are complicated by the inﬂuence
of many confounding variables (e.g., light, posture, meals,
and social interaction) [31, 32]. Keeping these diﬀerent
variables constant while measuring core body temperature,
studies examining diﬀerences and similarities in circadian
disturbances in groups of normal elderly and patients
with probable AD, as compared with a comparison group
of young, normal volunteers have shown a reduction in
endogenous circadian amplitude (ECA) and a delay in
endogenous circadianphase(ECP)ofcorebody temperature
in patients with probable AD [33, 34].
Studies have demonstrated that normal aging is accom-
panied by a 40% decrease in endogenous circadian ampli-
tude. Related studies showing a 50% reduction in amplitude
in the AD group, as compared with normal young subjects
could be interpreted as exaggerated or abnormal aging,
rather than any discrete eﬀect attributable to AD [30].
3.Common ADSymptoms RelatedtoCRDs
Insomnia, nocturnal behavioral changes, and excessive day-
time sleepiness, probably as a consequence of disrupted
nocturnal sleep, are the common AD symptoms related to
CRD. The actingout of REM sleep, often described as REM
behavior disorder, is also brieﬂy described here.
3.1. Insomnia. Insomnia in AD patients may have several
etiologies. Though it may be primarily related to the under-
lying neurodegenerative changes producing CRD described
above, other diﬀerential diagnostic issues need to be ruled
out. For example, breathing problems during sleep, such as
sleep apnea [35], with subsequent confusional arousal may
be a possibility. A treatment trial with a continuous positive
airway pressure (CPAP) breathing device has been reported
to improve insomnia and even cognitive function in some
patients.International Journal of Alzheimer’s Disease 3
Table 1: Changes in Sleep Parameters in AD.
Decrease in total sleep time
Decrease in eﬃciency of sleep with more fragmentation of sleep architecture
More time spent in stage 1 and stage 2 sleep and less time spent in deeper sleep
Increase in REM sleep latency and decreased REM sleep
Decreased density of eye movement activity
Insomniamayalsobesecondarytorestlesslegssyndrome
(RLS), where patients feel a need to pace in the evening or
night-time hours. Several studies have shown that the sever-
ity of leg discomfort follows a circadian rhythm, reaching a
peak after midnight. Most patients report diﬃculty falling
asleep or waking up shortly after sleep onset with unpleasant
leg sensations.
RLS, unlike the well-known mechanism of CRD, is
mainly due to striatal dopamine depletion. Deﬁcient iron
transport and metabolism are also believed to result in RLS.
I fc o n ﬁ r m e d ,s e r u mf e r r i t i nl e v e l sm a yp r o v et ob eau s e f u l
laboratory marker [36].
Another common cause of insomnia especially in insti-
tutionalizedorhospitalized ADpatientsmaybesecondaryto
noise in the environment and frequent room checks by staﬀ.
Bed checks are usually more frequent in incontinent patients
to avoid decubitus ulcers.
Superimposed delirium can also interfere with restful
night-time sleep. Simple measures such as treating urinary
tract infections and pain, relieving fecal impaction, and
reviewing the patient’s current medications to determine if
they may be promoting wakefulness or frequent awakenings
[37] can result in drastic improvements of sleep and
nocturnal agitation [38].
Macular degeneration and optic nerve degeneration are
common conditions seen in AD which limit light input,
further complicating circadian rhythms [39].
In patients with AD, other psychiatric comorbidities,
and in particular depression and anxiety, are also important
causes of insomnia. Treatment of these psychopathologies
may potentially ameliorate insomnia in AD patients.
Adding to sleep diﬃculties can be the excessive intake
of stimulants such as coﬀe e ,t e a ,o rc a ﬀeine containing
soft drinks. Theophylline, commonly used for broncho-
pulmonary disease, is also a frequent cause of insomnia
[40]. The cholinesterase inhibitors which are commonly
prescribed in AD, and in particular donepezil, have been
shown to occasionally cause insomnia [41, 42].
3.2. Hypersomnia. Excessive daytime sleepiness (Hypersom-
nia) is related to changes either in NREM (Idiopathic
hypersomnia), REM sleep (narcolepsy without cataplexy) or
could be central in origin (narcolepsy with cataplexy). Nar-
colepsy is seldom described as a degenerative disease of the
hypocreatin-containingneuronsinthelateralhypothalamus.
It may be accompanied by cataplexy or sudden loss of muscle
tone, vivid hallucinations, and brief periods of total paralysis
and REM sleep at inappropriate times. Patients experience
sudden urge to sleep which usually lasts for few seconds or
minutes. A mutation in chromosome 6 (controls the Human
Leukocyte Antigen) is seen in 90% to 100% of patients.
N a r c o l e p s yi su s u a l l ys e e ni ne a r l ya d u l t h o o da n di ti sv e r y
uncommon in elderly patients with AD [43].
In elderly, hypersomnia is more frequently seen in
patients with Parkinson disease (PD), Lewy body dementia
(DLB), or Parkinson disease dementia (PDD) than in
AD. A recently discovered hypothalamic wake-stimulating
neuropeptide, hypocretin-1, has been hypothesized to be
involved in consolidation of wakefulness. Lower hypocretin-
1 levels may be permissive for increased wake fragmentation
in AD resulting in daytime sleepiness. Stimulation of the
hypocretinsystemmaybeatherapeuticmeansforimproving
daytime wakefulness in AD and in turn it helps sleep
consolidation [44].
In AD patients, treatments of insomnia or medications
usedtocontrolagitationatnightareusuallythemostimpor-
tant causes of excessive daytime sleepiness (hypersomnia).
In addition, the use of anticonvulsants and strongly anti
cholinergic drugs such as antihistamines, antidiarrheals, and
drugs used to reduce bladder irritability can cause daytime
sedation and sleepiness [45].
Lack of engaging activities can also cause boredom
and daytime sleepiness. At times, caregivers may promote
daytime sleeping to ease their caregiving burden [46].
These in turn may result in night-time awakenings, further
worsening the CRD [47–49].
3.3. Sundowning. Sundowning refers to agitation or a
delirium-like state usually occurring late-afternoon/early
evening or at night. Individual behavioral components
of the condition which is frequently termed sundowning
include loud vocalization, wandering, physical aggression,
combativeness, maladaptive physical behaviors, and overall
agitation [50–55]. These behaviors usually start at around 4
PM and last as late as 11 PM. However, some studies have
reported the peak time of agitation as being in the afternoon,
at approximately 2:30 PM, rather than in the early evening
[56]. The prevalence of sundowning in AD ranges from 12%
t o2 5%[ 57].
The tendency for agitation in AD to occur at night
suggests that some changes in sleep and wakefulness in the
AD patient (chronobiologic changes) may reﬂect alterations
in the body’s ability to regulate the timing of certain
physiological events. Common factors which cause late day
confusion or “sundowning” include exhaustion, reduced
lighting, and increased shadows with inability to separate
dream from reality when sleeping. Agitation usually worsens
when patients are transferred to a new environment or a4 International Journal of Alzheimer’s Disease
new nursing home or when there is a change or shifting of
caregivers. “Sundowning” typically peaks in the middle stage
of the disease and then diminishes as AD progresses [58].
3.4. REM Sleep Behavior Disorder. RBD is classiﬁed as either
idiopathic or secondary to some identiﬁable causes. In most
cases, it is due to neurodegenerative diseases. Narcoleptic
patients may sometimes experience RBD due to degener-
ation of hypocreatin-containing hypothalamic neurons. It
may also be induced by some medications (e.g., sedative
hypnotics, tricyclic antidepressants, anticholinergics, selec-
tive serotonin reuptake inhibitors). Two case reports of
Rivastagmine-(cholinesterase inhibitor-) induced RBD have
been shown in AD patients [59].
REM sleep behavior disorder involves violent physical
activity during dreaming. It is due to failure of the mecha-
nism that produces atonia during REM sleep. There is a high
level of tonic and phasic muscle activity seen most typically
inREMsleep.Thisissuggestedbyelectromyographic(EMG)
activity recorded from facial and limb muscles during sleep.
This condition can be seen in AD patients’ comorbid with
synucleiopathies such as Parkinsons disease and/or Diﬀuse
Lewy Body dementia. Patients with REM sleep behavior
disorder may sustain injuries to themselves or their bed
partner. The disorder usually occurs in reaction to vivid
dreams.
REM sleep behavior disorder should be distinguished
from nocturnal paroxysmal dystonia (NPD) which is char-
acterized by abnormal night-time movement of the trunk
and head with alternating ﬂexing and extension of the
limbs.NPDisoftenconsideredtorepresentnocturnalfrontal
lobe epilepsy typically accompanied by abnormal slow wave
and spike activity with paroxysmal intrusions in NREM,
rather than REM sleep [61]. It is usually treated with
anticonvulsants such as carbamazepine [62–64], unlike REM
behavior Disorder which is usually treated with clonazepam
[65].
4. Treatment Approaches
There is empirical evidence to support the use of behavioral
and environmental strategies in alleviating sleep problems
and night-time behavioral disturbances in patients with AD.
There are also certain pharmacological approaches to treat
CRD-relatedsymptoms.However,oneneedstokeepinmind
that certain medications used for this purpose (e.g., ben-
zodiazepines) can worsen cognitive deﬁcits and obstructive
sleep apnea syndrome (a condition commonly associated
with AD). In addition, some medications may also induce
daytime sleepiness, resulting in night-time wakefulness.
4.1. Behavioral/Environmental Approaches. There are simple
and eﬀective interventions which should initially be tried to
treat CRDs in AD patients. These include a regular activity
schedule (e.g., serving dinner early), bed time routines,
decreasingnoiseandnight-timeexposuretoroomlevellight,
and limiting caﬀeine and alcohol intake [60]. Outpatients
and long-term care residents with AD may spend too much
time in bed and not enough time engaging in physical activ-
ities. This contributes to circadian rhythm abnormalities.
Hence, physical activity may inﬂuence circadian rhythms.
Mental, physical, and social activities to avoid boredom
and daytime napping may be useful. Carvalho-Bos et al.
used two-week actigraphic estimates of sleep-wake rhythm
and investigated its association with a range of functional
domains in 787 demented elderly women. They found that
nocturnal restlessness is related to impairment in daily
function and social interaction [66].
Typically, long-term care residents with AD are exposed
to only a few minutes of bright light each day, even less than
patients living in the community. Because light exposure
is the strongest known “Zeitgeber” (time cue) in humans,
lack of daytime light exposure may contribute to circadian
dysregulation [67, 68]. In one randomized controlled trial,
36 community-dwelling patients withADwerestudied using
a sleep survey and wrist actigraphy. Cases were randomized
to daily exercise plus 60 minutes daily of bright light therapy
(BLT) versus controls for 2 months. There was a signiﬁcant
reduction in the number of night-time awakenings, total
time awake at night, and depression (P<. 05) in the
treatment group. Patients were also followed for the next 6
months and beneﬁts were maintained [69, 70].
In institutionalized patients, BLT has been shown to
reduce daytime nap duration by 30 minutes during the
treatment period (P<. 004) [70–72]. However, the eﬀect
in another study was not sustained after the cessation of
light therapy [69, 73]. Another study has demonstrated
modest beneﬁts of bright light for two weeks on acti-
g r a p h i cm e a s u r e m e n t so fa c t i v i t y[ 74–76]. A long-term (5
years) double blind, placebo-controlled randomized trial
performed on 189 residents of 12 group care facilities in
Netherlands has shown another modest beneﬁt of bright
light therapy in improving some of the cognitive and
noncognitive symptoms of dementia. This eﬀect is more
attenuated when combined with melatonin administration
[77, 78]. In summary, regular exposure to bright light may
beeﬀectiveforday/nightreversalproblems[73,79–81].Ifthe
patient has RBD, removing potentially dangerous items from
the bedroom and placing a soft mattress next to the bed may
also help to ensure safety.
Clinical experience-based data alsosuggestthatsome AD
patients with obstructive sleep apnea syndrome, treated with
CPAP, may beneﬁt from improved sleep consolidation [82–
84]. It is recommended that behavioral and environmental
techniques should be tried ﬁrst before resorting to pharma-
cologic approaches.
4.2. Pharmacological Approaches. There are various medi-
cations to treat insomnia, behavioral dyscontrol, and noc-
turnal agitation/wandering, excessive daytime sleepiness,
REM sleep behavior disorder, and restless legs syndrome.
Medications should always be combined with environmen-
tal/behavioral modiﬁcations. The choice of agent to use and
dosing must be individualized. It is also the responsibility
of the clinician to consider potential side eﬀects and drug
interactions.International Journal of Alzheimer’s Disease 5
Table 2: Dosing schedule of medications used in CRD.
Symptom Medication Initial Dose Titrating Schedule Maximum Daily Dose
Insomnia
Trazodone 25mg hs 25mg increments q 3–5 days 50–100mg
Zolpidem 5mg hs 5mg increments q 3-4 days 5–10mg
Mirtazapine 15mg hs 15mg q week 15–30mg
Quetiapine 25mg hs 25mg increments q 3-5 days 25–100mg
Chloral hydrate 250mg hs 250mg increments q 5–7 days 250–1000mg
Behavioral Dyscontrol
Memantine 5mg am 5mg increments q week 20mg
Donepezil 5mg am 5mg increments in 4 weeks 5–10mg
Rivastigmine Transdermal 4.6mg od 9.5mg 4 weeks later 9.5mg
Galantamine ER 8mg od 8mg increments q 4 weeks 16–24mg
Risperidone 0.25mg hs 0.25mg increments q week 0.5–1.5mg
Olanzapine 2.5mg hs 2.5mg increments q week 5–10mg
Carbamazepine (check level) 100mg hs 100mg increments q 3-5 days bid or tid 600mg
Oxcarbazepine 300mg hs 300mg increments q week 2400mg
Divalproex ER (check level) 125mg hs 125mg increments q 3-4 days 1500mg
Excessive Daytime Sleepiness Methylphenidate 2.5mg am 2.5mg increments am and early pm 20mg
Modaﬁnil 100mg am 100mg increments q week 200mg
REM Sleep Behavior Disorder Clonazepam 0.25mg hs 0.25mg increment q week 1mg
Melatonin 3mghs add3mgifneeded 6mg
Adapted from Current management of sleep disturbances in dementia: [60].
Insomnia is a common problem which if left untreated/
undertreatedmayexacerbatethe cognitive and non cognitive
symptoms of AD. Commonly used medications to promote
sleep include trazodone, zolpidem, sedating antidepressants
such as mirtazapine, less commonly, low doses of sedating
atypical antipsychotics such as quetiapine, and chloral hyd-
rate. (Refer to Table 2 for dosing). In considering the use
of antipsychotics in the AD population, the FDA-issued
warnings about increased risks of mortality, stroke, and
stroke-likeeventsneedtobeconsideredaspartofrisk/beneﬁt
calculations. As much as possible it is best to avoid benzo-
diazepines as they may worsen cognitive functions in AD
patients. They can also impair balance and increase the risk
of falls.
Nocturnal agitation/wandering, physical and verbal
aggression, and hallucinations can also be treated pharma-
cologically after ruling out other medical and environmen-
tal causes and a trial of behavioral techniques. Atypical
antipsychotics [85–87], anticonvulsants, short-acting benzo-
diazepines such as lorazepam or longer-acting agents (e.g.,
clonazepam), and trazodone may be eﬀective measures.
(Refer to Table 2 for dosing).
Cholinesterase inhibitors such as donepezil, rivastig-
mine, and galantamine may improve nocturnal behaviors
over time [88, 89]. Cholinesterase inhibitors may signif-
icantly decrease evening-time hallucinations seen in AD
patients [89]. Because of the dependence of REM sleep
on the integrity of the cholinergic system, theoretically,
one may predict increased REM sleep in cholinesterase
inhibitor-treated AD patients [90]. Studies have found that
rivastigmine increases the density of REM sleep in normal
subjects [91]. However, cholinesterase inhibitors, especially
donepezil, are also known to increase vivid dreams which
subsequently may result in further disturbance in sleep
[92, 93]. A double-blind placebo-controlled trial done by
Grossberg et al. has shown that AD patients who received
memantine performed better on behavioral outcomes com-
pared to placebo [94].
Clonazepam, started at a low dose of 0.25mg at night, is
proventobeeﬀectiveinthetreatmentofREMsleepbehavior
disorders [65]. Melatonin [95, 96] or pramipexole [97]c a n
also be used in such cases although they are not as eﬀective
as clonazepam.
Although their use at higher doses is limited because of
their potential for cardiovascular side eﬀects in elderly, lower
doses of methylphenidate or modaﬁnil can be used if exces-
sivedaytimesleepinessisaproblem.Asusual,therisk/beneﬁt
ratio of these agents needs to be considered and discussed
with patient/family before initiating these medications. It is
also worth noting that stimulants may worsen some features
of “sundowning ”, for example, hallucinations.
Restless leg syndrome is a common condition which is
not uncommonly seen in AD patients and which can further
complicate CRD. Pramipexole 0.25mgp.o. hs or ropinirole
0.5mgp.o. hs are the commonly prescribed medications for
this condition. The stimulating dopaminergic eﬀect of these
medicines can worsen sleep disturbance in some patients
[65].
5. Recommendations/Conclusions
There are several causes of and contributors to CRD in AD.
It is always important to rule out other potentially treatable
comorbidities such as depression and delirium.
Caregiver understanding of the nature of AD and the
implementationofenvironmentalandbehavioraltechniques6 International Journal of Alzheimer’s Disease
can reduce both patient and caregiver distress and may
decrease hospital readmissions and delay institutionaliza-
tion. We are beginning to understand the neuroanatomic,
neurochemical, and endocrine underpinnings of CRDs in
AD and their impact on sleep/wake disturbances as well
as common behavioral abnormalities. At present, there is
no deﬁnitive treatment to address the neurodegenerative
changesunderlyingCRDsinAD.However,currenttherapies,
whether behavioral/environmental or pharmacotherapeutic,
can provide symptomatic beneﬁts for patients and relieve
stress on their family or professional caregivers.
Largecontrolled studies are needed to evaluatethe eﬀects
of treatments such as BLT and engaging daytime activities
in the reduction of CRDs and resultant sleep/wake cycle and
behavioral disturbances in AD patients.
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